Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.

Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA
J Thorac Oncol. 2011 6 (6): 1128-31

PMID: 21623279 · PMCID: PMC3230574 · DOI:10.1097/JTO.0b013e3182161508

MeSH Terms (21)

Adenocarcinoma Adult Aged Aged, 80 and over Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Dasatinib Drug Resistance, Neoplasm ErbB Receptors Erlotinib Hydrochloride Female Gefitinib Humans Lung Neoplasms Male Middle Aged Protein Kinase Inhibitors Pyrimidines Quinazolines Thiazoles Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: